Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma-Reference-Cited by-同舟云学术

Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

Published:2021-09 Issue:5 Volume:7 Page:1084-1091
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Bedke Jens,Merseburger Axel S.,Loriot Yohann,Castellano Daniel,Choy Ernest,Duran Ignacio,Rosenberg Jonathan E.,Petrylak Daniel P.,Dreicer Robert,Perez-Gracia Jose L.,Hoffman-Censits Jean H.,Van Der Heijden Michiel S.,Pavlova Julie,Thiebach Lars,de Ducla Sabine,Fear Simon,Powles Thomas,Sternberg Cora N.

Funder

F. Hoffmann-La Roche Ltd, Basel, Switzerland

Publisher

Elsevier BV

Subject

Urology

Reference12 articles.

1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

2. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial;Patel;Lancet Oncol,2018

3. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study;Powles;JAMA Oncol,2017

4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

5. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial;Sharma;Lancet Oncol,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors;Clinical Genitourinary Cancer;2024-10

2. A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study;Journal of Investigative Dermatology;2023-10

3. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors;Journal for ImmunoTherapy of Cancer;2023-01

4. A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score;Minerva Urology and Nephrology;2022-12

5. A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study. The urInary TrAct CArcinoma score (ITACA);2022-08-31